Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Selectivity interaction (Z?-LYTE assay (SelectScreen Invitrogen)) EUB0000690a PTK2B
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Selectivity interaction (Enzymatic assay) EUB0000609a PTK2B
Selectivity interaction (Ambit kinase binding assay panel) EUB0000609a PTK2B
Assay data:1 Tested
SummaryRelated BioAssays by Target
Affinity Biochemical interaction (Binding assay) EUB0000138c PTK2B
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
Affinity Biochemical interaction (Binding assay) EUB0000702a PTK2B
Inhibition of PYK2 (unknown origin) at 10 nM relative to control
SummaryPubMed CitationRelated BioAssays by Target
PYK2 DiscoveRx kinase panel
Pyk2(h) Kinase panel
Inhibition of PYK2 (unknown origin) at 1 uM
Binding affinity to wild-type human full length PYK2 (M1 to E967 residues) expressed in bacterial expression system assessed as residual binding level at 100 nM by Kinomescan method relative to control
Induction of PYK2 degradation in human MDA-MB-231 cells assessed as protein stability at 50 ug/ml after 8 hrs
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Induction of PYK2 degradation in human MDA-MB-231 cells at 10 nM treated for 16 hrs followed by compound washout and measured after 48 hrs by Western blot analysis
Induction of PYK2 degradation in human MDA-MB-231 cells at 10 nM after 1 to 2 hrs by Western blot analysis
Induction of PYK2 degradation in human SR cells at 1 nM after 16 hrs by Western blot analysis
Inhibition of PYK2 (unknown origin) assessed as residual activity at 1 uM relative to control
Assay data:5 Tested
Biochemical Assay from US Patent US9428508: "2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors"
Assay data:156 Active, 161 Activity ≤ 1 µM, 161 Tested
Inhibition Assay from US Patent US9518060: "Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors"
Assay data:94 Active, 5 Activity ≤ 1 nM, 94 Activity ≤ 1 µM, 94 Tested
KinomeScan assay: inhibition of PYK2
Assay data:1 Active, 108 Tested
SummaryCompounds, ActiveRelated BioAssays by Target
PYK2(PT2BLHF1) Takeda global kinase panel
Assay data:1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, activity ≤ 1 µMRelated BioAssays by Target
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on